VCYT
VERACYTE, INC.
NASDAQ · Healthcare · Biotechnology · US
$39.80
−1.91%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$40.52
From 52W high−34.21%
Volume2.67M
Market cap$3.20B
P/E (TTM)27.6x
P/S (TTM)5.7x
Div yield—
Key dataSep 18, 2026
Open
$40.52
From 52W high
−34.21%
Volume
2.67M
Market cap
$3.20B
ValuationView details →
P/E (Fwd)
22.1x
EV/EBITDA
21.2x
P/E (TTM)
27.6x
RSI (14)
39.6
MomentumView details →
1D Return
−1.91%
YTD Return
−4.94%
SummaryUpdated Jun 1, 2026
Veracyte, Inc. (NASDAQ:VCYT) is a molecular diagnostics company founded in 2006 and headquartered in South San Francisco, California. Originally incorporated as Calderome, Inc., the company changed its name to Veracyte in March 2008 and went public in October 2013. Veracyte has evolved from a single-product thyroid cancer diagnostics company into a diversified genomic testing platform serving multiple cancer types including prostate, breast, lung, and colon cancers.
Similar companies
Latest newsMore news →
Veracyte acquired Convergent Genomics, expanding its urology diagnostics portfolio with a urinary tumor DNA testing platform for bladder cancer care.6d agoBank of America Corp DE increased its stake in Veracyte, Inc. by 14.7% during the first quarter, acquiring an additional 185,929 shares, according to its SEC filing.38d ago